<Table> <Tr> <Th> Type </Th> <Th> Survival Rate </Th> </Tr> <Tr> <Td> Oral Cancer </Td> <Td> 64.5 % </Td> </Tr> <Tr> <Td> Lip cancer </Td> <Td> 90 % </Td> </Tr> <Tr> <Td> Hypopharynx cancer </Td> <Td> 33 % </Td> </Tr> <Tr> <Td> Esophageal cancer </Td> <Td> 19 % </Td> </Tr> <Tr> <Td> Stomach cancer </Td> <Td> 30.6 % </Td> </Tr> <Tr> <Td> Small intestine cancer </Td> <Td> 67.5 % </Td> </Tr> <Tr> <Td> Colorectal cancer </Td> <Td> 64.9 % </Td> </Tr> <Tr> <Td> Hepatic and bile duct cancer </Td> <Td> 17.6 % </Td> </Tr> <Tr> <Td> Gallbladder cancer </Td> <Td> 18.2 % </Td> </Tr> <Tr> <Td> Pancreatic cancer ( all types ) </Td> <Td> 8.2 % </Td> </Tr> <Tr> <Td> Laryngeal cancer </Td> <Td> 60.7 % </Td> </Tr> <Tr> <Td> Lung cancer ( all types ) </Td> <Td> 18.1 % </Td> </Tr> <Tr> <Td> Mesothelioma </Td> <Td> 9 % </Td> </Tr> <Tr> <Td> Tracheal cancer </Td> <Td> 52.9 % </Td> </Tr> <Tr> <Td> Bone cancer ( all types ) </Td> <Td> 67.7 % </Td> </Tr> <Tr> <Td> Soft tissue , not otherwise specified </Td> <Td> 64.4 % </Td> </Tr> <Tr> <Td> Skin cancer ( excluding basal and squamous ) </Td> <Td> 91.7 % </Td> </Tr> <Tr> <Td> Breast cancer </Td> <Td> 89.7 % </Td> </Tr> <Tr> <Td> Breast cancer in situ </Td> <Td> 100 % </Td> </Tr> <Tr> <Td> Uterine cancer </Td> <Td> 29.8 % - 82.7 % </Td> </Tr> <Tr> <Td> Ovarian cancer </Td> <Td> 46.5 % </Td> </Tr> <Tr> <Td> Cervical cancer </Td> <Td> 67.1 % </Td> </Tr> <Tr> <Td> Prostate cancer </Td> <Td> 98.6 % </Td> </Tr> <Tr> <Td> Testicular cancer </Td> <Td> 95.1 % </Td> </Tr> <Tr> <Td> Bladder cancer </Td> <Td> 77.3 % </Td> </Tr> <Tr> <Td> Renal cancer </Td> <Td> 74.1 % </Td> </Tr> <Tr> <Td> Ocular cancer </Td> <Td> 82.7 % </Td> </Tr> <Tr> <Td> Glioblastoma </Td> <Td> 4 % </Td> </Tr> <Tr> <Td> Diffuse Intrinsic Pontine Glioma </Td> <Td> 0 % </Td> </Tr> <Tr> <Td> Myeloma </Td> <Td> 49.6 % </Td> </Tr> <Tr> <Td> Hodgkin 's lymphoma </Td> <Td> 86.4 % </Td> </Tr> <Tr> <Td> Non-Hodgkin's lymphoma </Td> <Td> 71 % </Td> </Tr> <Tr> <Td> Thyroid cancer </Td> <Td> 98.2 % </Td> </Tr> <Tr> <Td> Leukemia ( Acute lymphocytic ) </Td> <Td> 68.2 % </Td> </Tr> <Tr> <Td> Leukemia ( Acute myelomonocytic ) </Td> <Td> 24 % </Td> </Tr> <Tr> <Td> Leukemia ( Chronic lymphocytic ) </Td> <Td> 83.2 % </Td> </Tr> <Tr> <Td> Leukemia ( Chronic myeloid ) </Td> <Td> 66.9 % </Td> </Tr> </Table>
<Table> <Tr> <Th> Type </Th> <Th> Survival Rate </Th> </Tr> <Tr> <Td> Oral Cancer </Td> <Td> 64.5 % </Td> </Tr> <Tr> <Td> Lip cancer </Td> <Td> 90 % </Td> </Tr> <Tr> <Td> Hypopharynx cancer </Td> <Td> 33 % </Td> </Tr> <Tr> <Td> Esophageal cancer </Td> <Td> 19 % </Td> </Tr> <Tr> <Td> Stomach cancer </Td> <Td> 30.6 % </Td> </Tr> <Tr> <Td> Small intestine cancer </Td> <Td> 67.5 % </Td> </Tr> <Tr> <Td> Colorectal cancer </Td> <Td> 64.9 % </Td> </Tr> <Tr> <Td> Hepatic and bile duct cancer </Td> <Td> 17.6 % </Td> </Tr> <Tr> <Td> Gallbladder cancer </Td> <Td> 18.2 % </Td> </Tr> <Tr> <Td> Pancreatic cancer ( all types ) </Td> <Td> 8.2 % </Td> </Tr> <Tr> <Td> Laryngeal cancer </Td> <Td> 60.7 % </Td> </Tr> <Tr> <Td> Lung cancer ( all types ) </Td> <Td> 18.1 % </Td> </Tr> <Tr> <Td> Mesothelioma </Td> <Td> 9 % </Td> </Tr> <Tr> <Td> Tracheal cancer </Td> <Td> 52.9 % </Td> </Tr> <Tr> <Td> Bone cancer ( all types ) </Td> <Td> 67.7 % </Td> </Tr> <Tr> <Td> Soft tissue , not otherwise specified </Td> <Td> 64.4 % </Td> </Tr> <Tr> <Td> Skin cancer ( excluding basal and squamous ) </Td> <Td> 91.7 % </Td> </Tr> <Tr> <Td> Breast cancer </Td> <Td> 89.7 % </Td> </Tr> <Tr> <Td> Breast cancer in situ </Td> <Td> 100 % </Td> </Tr> <Tr> <Td> Uterine cancer </Td> <Td> 29.8 % - 82.7 % </Td> </Tr> <Tr> <Td> Ovarian cancer </Td> <Td> 46.5 % </Td> </Tr> <Tr> <Td> Cervical cancer </Td> <Td> 67.1 % </Td> </Tr> <Tr> <Td> Prostate cancer </Td> <Td> 98.6 % </Td> </Tr> <Tr> <Td> Testicular cancer </Td> <Td> 95.1 % </Td> </Tr> <Tr> <Td> Bladder cancer </Td> <Td> 77.3 % </Td> </Tr> <Tr> <Td> Renal cancer </Td> <Td> 74.1 % </Td> </Tr> <Tr> <Td> Ocular cancer </Td> <Td> 82.7 % </Td> </Tr> <Tr> <Td> Glioblastoma </Td> <Td> 4 % </Td> </Tr> <Tr> <Td> Diffuse Intrinsic Pontine Glioma </Td> <Td> 0 % </Td> </Tr> <Tr> <Td> Myeloma </Td> <Td> 49.6 % </Td> </Tr> <Tr> <Td> Hodgkin 's lymphoma </Td> <Td> 86.4 % </Td> </Tr> <Tr> <Td> Non-Hodgkin's lymphoma </Td> <Td> 71 % </Td> </Tr> <Tr> <Td> Thyroid cancer </Td> <Td> 98.2 % </Td> </Tr> <Tr> <Td> Leukemia ( Acute lymphocytic ) </Td> <Td> 68.2 % </Td> </Tr> <Tr> <Td> Leukemia ( Acute myelomonocytic ) </Td> <Td> 24 % </Td> </Tr> <Tr> <Td> Leukemia ( Chronic lymphocytic ) </Td> <Td> 83.2 % </Td> </Tr> <Tr> <Td> Leukemia ( Chronic myeloid ) </Td> <Td> 66.9 % </Td> </Tr> </Table>
which type of cancer has the poorest prognosis
which type of cancer has the poorest prognosis
Diffuse Intrinsic Pontine Glioma
Diffuse Intrinsic Pontine Glioma